B+
Bull case
25%
Probability
Target price
$11.00
+109.1% vs current
ANNX
AnnexonCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$6.50
+23.6% vs current
B-
Bear case
25%
Probability
Target price
$3.00
-43.0% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+77.6
Score
AI commentary
Sentiment is cautiously constructive but not strong. The company has credible, dated primary-source milestones and cash into the second half of 2027, which supports continued operations, yet the decisive re-rating drivers sit in late-2026 clinical and regulatory events with meaningful failure and delay risk [#IR-2026-03-30] [#10-K-2026-03-30]. Given the deterministic prior is neutral with mildly negative forward-return bias and only moderate evidence quality, this looks more like a watchlist/speculative setup than a clean conviction long.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30catalystRunway helps near term, but ATM and future financing remain overhangsHigh impact
Annexon ended 2025 with about $238.3 million in cash and short-term investments and guides runway into the second half of 2027, yet the 10-K also discloses a new March 30, 2026 sales agreement allowing up to $150 million of common-stock issuance, following the November 2025 equity raise; that limits immediate distress but leaves dilution risk live if data or timelines slip [#10-K-2026-03-30] [#PR-2025-11-12].
2026-10-31eventFORWARD data and planned 2026 BLA path for tanruprubartHigh impact
Management says initial U.S./European FORWARD data are expected in 2026 and are intended to support a planned BLA submission for tanruprubart in GBS, but the 10-K also states FDA may view the generalizability package as insufficient without additional patient data, keeping regulatory risk elevated [#10-K-2026-03-30] [#IR-2026-03-30].
2026-11-15eventARCHER II Phase 3 topline data in GAHigh impact
Annexon says topline data from the pivotal Phase 3 ARCHER II trial of vonaprument in geographic atrophy is expected in Q4 2026; the same filing and IR materials frame this as the key value-driving milestone, but outcome risk remains binary for a single late-stage asset [#10-K-2026-03-30] [#IR-2026-03-30].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology